logo
6 surprising signs you're lonely according to experts

6 surprising signs you're lonely according to experts

Yahoo13-06-2025
Loneliness is a deeply personal experience that can affect anyone, often in ways we don't immediately recognise.
While it's easy to associate it with being physically alone, the reality is far more nuanced. Loneliness can be emotional, social, or even existential, manifesting through feelings of disconnection, emptiness, or being misunderstood, even when surrounded by others.
As Loneliness Awareness Week (9–15 June) reminds us, this feeling is not a personal failure or weakness; it's a natural part of life that most people experience at some point.
According to the Campaign to End Loneliness, in 2022, nearly half (49.63%) of adults in the UK – approximately 26 million people – reported feeling lonely at least occasionally, with some saying they felt lonely often or always.
But loneliness doesn't always show up in obvious ways. Yahoo UK spoke to two experts to unpack the lesser-known signs and offer advice on what you can do if you're struggling.
Relationship expert and British Association for Counselling and Psychotherapy-accredited counsellor, Georgina Sturmer tells Yahoo UK: "When we feel lonely, it can be tempting to fill our diary with as much as possible or surround ourselves with people all the time. But the problem is that when we feel lonely, what we really crave is not the company of lots of others but a real sense of connection."
Sturmer says that it is possible to feel lonely in a crowded room, to which Ruth Lowe, the head of loneliness services at the charity Age UK, agrees. She adds that the key to tackling this feeling is forming meaningful relationships.
"If you're out with lots of people, but you don't actually feel connected to them or like they care about you, or you don't have any meaningful connection there, then you can feel even lonelier," she explains.
Lowe says that loneliness can also result in people declining social invitations.
"Somebody declining invites and not engaging in things they used to might think, 'Maybe I'm declining these things because I don't want to go anymore.' But it could be that you are feeling lonely and you are struggling with your confidence," she continues.
"Loneliness can bring up a lot of negative thoughts and feelings. People might actually start to feel nervous about going to things and start thinking, 'Does anybody actually want me there?' Because it impacts your self-worth."
Lowe says that loneliness can result in you feeling angrier or more emotional than usual.
"You might find that things are continuing to go round in your head, and maybe you're overthinking things. You might experience moods that make you behave or act in ways that you don't usually," she explains.
"Loneliness isn't a mental health condition, but it is closely linked to our mental health and our mental wellbeing."
Loneliness also might inhibit you from taking time off work, or it might drive you to say 'yes' to extra projects, even if you're already feeling stressed.
"Work might be full of pressure and deadlines, but it often offers us a certain level of structure and an opportunity to escape from other worries," Sturmer explains.
The counsellor says you may also experience "free time anxiety," explaining that in a society that prizes friendship, spending time alone can make you feel like a failure.
2.1 million older people (15%) say they take less care of themselves when they're lonely, according to research by Age UK.
"Loneliness can make it feel like there's no point in your existence, that you don't have a purpose. That might mean that you're struggling to make the effort and get the motivation to take care of yourself, to take care of the space that you live in," Lowe shares.
This sign of loneliness is cross-generational, as Sturmer states that it can result in anyone feeling like they are "not good enough," leading to low self-esteem.
"When we think about self-care – eating well, exercising, getting out in the fresh air – it's important to recognise that we are only able to look after ourselves if we feel that we deserve to do so," she says.
"And then it becomes harder to prioritise ourselves and to do the things that we need to do in order to feel healthy and well."
According to Sturmer, when you're in a state of loneliness, it's natural to crave connection. While people will often seek comfort online, she warns against this.
"At a very surface level, it might feel that scrolling on social media delivers us a sense of connection, so we can find ourselves scrolling mindlessly through our newsfeed. However, that social media feed might actually amplify our loneliness," she says.
Some people turn to drugs and alcohol to help them ignore their feelings of loneliness. Lowe explains: "Loneliness can make you feel like you've got very little self-worth, and people might try and find solace in using drugs or alcohol to try and make themselves feel better, to try and numb how they're feeling."
Lowe recommends speaking to someone about your feelings, whether it be a family member, friend or a GP.
"We know that talking about loneliness can be difficult. It can take a lot of courage, but the most powerful thing you can do for yourself is speak to someone and say the words out loud," she says.
"1.1 million older people feel embarrassed to talk about their feelings of loneliness, and they might not feel as comfortable as younger people do to talk about their emotions and their mental health. Older people can contact Age UK for support, and there are other organisations out there for different groups of people."
Lowe says it's important to take small steps to improve your situation. She advises against joining multiple groups and clubs at once, as that could be overwhelming.
"Try and take small steps. It could just be something like, 'I'm going to try and reach out to a friend that I haven't spoken to for a little while. I'm going to send them a message or give them a call.' Don't put too much pressure on yourself to do too much too soon, especially if you are feeling quite down about yourself."
Volunteering is a great way to expand your social circle and can help when you're experiencing any negative feelings.
"Meet new people, give yourself a sense of purpose, and give yourself some routine. Having people relying on you and going to do something can really help," Lowe says.
Read more about loneliness:
Loneliness increases as we age, study suggests (PA Media, 3-min read)
5 ways loneliness can negatively affect your health (PA Media, 4-min read)
The loneliness myth: what our shared stories of feeling alone reveal about why you can't 'fix' this very human experience (The Conversation, 15-min read)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Holding too long or going too much: 7 toilet habits an expert wants you to stop
Holding too long or going too much: 7 toilet habits an expert wants you to stop

Yahoo

time01-08-2025

  • Yahoo

Holding too long or going too much: 7 toilet habits an expert wants you to stop

An expert reveals the bladder behaviours to break – and what to do instead. Whether you're off on holiday or just navigating a UK heatwave, your bladder habits may not be top of mind this summer. But holiday season – with its long journeys, disrupted routines, unfamiliar loos and hotter weather – can be a time when some of us fall into poor peeing patterns. According to Helen Lake, a urology specialist nurse at The Urology Foundation, warmer weather and busier routines can lead to bladder mistakes. "We're on the go, often dehydrated, and not always paying attention to when or how we go to the toilet," she tells Yahoo UK. Over time, these habits could strain your pelvic floor, raise your risk of infection and may make bladder control worse. So, how should we really be going? And what habits should we leave behind this holiday season? Here are seven bladder mistakes to watch out for – and what to do instead. 1. Going 'just in case' Doing a quick wee before heading out might feel like smart planning, especially when you're travelling – but if you do it too often, you could actually be doing your bladder more harm than good. "Going too frequently – especially when your bladder isn't full – can teach it to send 'full' signals earlier than necessary," says Lake. "Over time, this can make the bladder more sensitive and lead to a pattern of urgency and needing to wee often." What to do: Go when your bladder feels comfortably full, not out of habit. 2. Holding it in too long On the flip side, holding on for too long, whether it's during a long journey or when you're out and about, isn't ideal either. It can stretch the bladder and strain the pelvic floor. "Holding on too long means the pelvic floor and bladder outlet muscles stay tense for extended periods to keep urine in," Lake explains. "If this becomes a frequent habit, it can lead to muscle fatigue or tightness, especially in people with existing weakness or pelvic floor dysfunction... making it harder to empty fully." What to do: Make regular toilet stops. You can use a toilet-finder app, like Flush, to find public conveniences when you're somewhere new. If you live with a bladder condition, consider carrying a RADAR key to open disabled toilets or a 'Just Can't Wait' card, which helps to quickly explain your situation. 3. Drinking too little – or too much Hydration habits often change during summer, and can affect your bladder. Not drinking enough can make urine more concentrated and irritating to the bladder, while overloading on fluids can lead to an unsettled bladder. "Aim for 1.5–2 litres per day, unless advised otherwise. This becomes more important with age," explains Lake. "As you slide towards your 50s, 60s and 70s, your sense of thirst starts to blunt, so you may not feel thirsty even when you're dehydrated." What to do: "Sip steadily throughout the day, especially in hot weather or when flying, to prevent dehydration and reduce infection risk. More isn't always better," she says. "Constantly sipping large amounts can lead to frequent urges." 4. Snacking on the wrong things From fizzy drinks on flights to crisps and cocktails by the pool, summer holidays often bring more bladder irritants into the mix. "It's wise to avoid alcohol before or during long journeys; it can irritate the bladder, act as a diuretic (making you wee more), and contribute to dehydration," Lake says. And it's not just what you drink. "Salty snacks like nuts, crisps, and so on, all lead to your kidneys holding on to fluid for your cells and blood pressure,' she explains. 'Your urine becomes more concentrated, which, again, can irritate the bladder." What to do: Choosing water and hydrating foods like fruit, instead of overly processed snacks, can help keep things in balance. 5. Hovering Trying to avoid contact with public toilet seats might seem sensible, but hovering can cause its own issues. 'Hovering over toilets prevents the pelvic floor from fully relaxing, which can lead to incomplete bladder emptying,' Lake says. 'Over time, this may increase the risk of urinary tract infection (UTI) and leave you feeling like you need to go again soon after.' What to do: When possible, sit down fully. "Being in a rush and poor positioning on the toilet can affect how you empty your bladder. Take the time to fully empty,' she explains. 6. Forcing urine out Pushing or bearing down to speed things up on the loo can be more harmful than you might think. "Forcing urine out or straining puts pressure on the bladder and pelvic floor muscles," says Lake. 'It can lead to prolapse or poor bladder emptying.' What to do: If you're regularly pushing to wee, your muscles may not be relaxing and it's worth speaking to a professional. 7. Wiping the wrong way If you're out of your usual routine, it's easy to forget good hygiene habits. But wiping wrong can raise your risk of infection. 'Always wipe from front to back after peeing. This helps prevent the spread of bacteria from the back passage to the urethra, which can lead to UTIs,' says Lake. What to do: Wipe front to back NOT back to front. When should you worry about your wee? Sometimes, what seems like a minor irritation will settle on its own. But if it doesn't, it could be a sign of a urinary tract infection or something more. Lake says to watch out for: Cloudy urine Blood in urine Pain or stinging when passing urine A strong, persistent urge to go Feeling unwell, nauseous, shaky, or having a temperature Pain in the lower back or sides "If any symptom doesn't get better within the first few hours, you may need medical treatment. And if your temperature's up, or you're feeling shaky and unwell, that's urgent,' Helen says. "It's a sign the infection may have moved to the kidneys." If you need any help or advice, you can contact The Urology Fpoundation's confidential UTI Information Service and Helpline on 0808 801 1108 or email nurse@ Read more about toilet habits: 6 toilet habit changes you should always see a doctor about (Yahoo Life UK, 4-min read) How 'blowing bubbles' and 'mooing' can help ease constipation, according to NHS doctor (Yahoo Life UK, 4-min read) Bowel cancer cases in young people rising sharply in England, study finds (PA Media, 4-min read) Solve the daily Crossword

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Business Wire

time30-07-2025

  • Business Wire

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company's PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable. 'The launch of our liquid biopsy test positions us at the forefront of the precision oncology market,' said Tony Zook, Chief Executive Officer, NeoGenomics. 'As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It's a strategic milestone that underscores our commitment to sustainable growth and clinical leadership.' Using circulating tumor DNA (ctDNA) from a simple blood draw, PanTracer LBx provides access to biomarker information when tissue samples are insufficient or unavailable. The test is designed to offer a seven-day turnaround time and analyze over 500 genes, including MSI and bTMB, to deliver timely, actionable insights. When indicated, it can be ordered as a standalone option, as a reflex when tissue testing fails, or concurrently with tissue analysis. Clinical applications include therapy selection, trial matching, and longitudinal monitoring. PanTracer LBx strengthens NeoGenomics' pan-solid tumor CGP portfolio, working seamlessly with tissue-based options like PanTracer Tissue, providing a testing strategy across a range of solid cancers. Complemented by a broad portfolio of testing services and dedicated clinical support, the launch expands NeoGenomics' position in the growing $3–5 billion liquid biopsy market and advances its goal of delivering deep insights to more patients across diverse care settings. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ LBx in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ LBx, the speed and utility of the results generated, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and in the 'Investors' section of our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website

Business Upturn

time28-07-2025

  • Business Upturn

Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website

Business Wire India Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: . Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store